Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense This study is testing a new medicine called **tibulizumab** for a skin condition known as **hidradenitis suppurativa (HS)**. HS causes painful lumps under the skin. The research is being done in two parts. In the first part, which lasts 16 weeks, some adults will get tibulizumab, while others will get a placebo (a harmless pill that has no effect). Neither the participants nor the doctors will know who gets what. This is called a **double-blind** study. In the second part, also 16 weeks, everyone will get tibulizumab. To join, you must be between 18 and 70 years old, have had HS for at least 6 months, and have at least 5 abscesses or swollen lumps. Some people, like those with certain infections or a lot of draining tunnels, cannot join. Key Points:

• The study lasts a total of 32 weeks.
• Participants will need to tolerate medicine given under the skin.
• Not suitable for those with some infections or high draining tunnel count.